Opendata, web and dolomites

D2P SIGNED

Diabeloop to Patients: An Artificial Pancreas solution to improve the balance, safety and autonomy of 20 million people

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 D2P project word cloud

Explore the words cloud of the D2P project. It provides you a very rough idea of what is the project "D2P" about.

periods    adoption    telemedicine    solution    worldwide    coma    sensor    secured    industrialisation    generation    sweden    optimisation    seizures    daily    countless    mimic    diseases    causes    cells    t1d    closed    components    delivered    age    connected    handset    fainting    producing    reduce    identification    diabetes    hosting    upgrade    patient    dose    complementary    dblg1    autoimmune    adjustments    physiological    20    models    storage    diabeloop    algorithms    insulin    continuous    beta    goals    stressful    people    first    blindness    day    appropriate    patients    core    netherlands    countries    death    france    model    glucose    made    alleviate    half    specificities    basis    automatically    personalised    foreign    destruction    function    severe    million    hypoglycaemia    exchange    hyperglycaemia    pancreas    integrates    loop    telemonitoring    customisation    heart    pump    suggest    complications    professional    burden    situations    innovation    device    data    validate    performances    treatment    begin    breakthrough    artificial    market    regulating    intelligence    amputations    clinicians    calculate    healthcare    anyone    monitoring    regulation    healthy    renal   

Project "D2P" data sheet

The following table provides information about the project.

Coordinator
DIABELOOP 

Organization address
address: 155-157 COURS BERRIAT
city: GRENOBLE
postcode: 38028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙190 €
 EC max contribution 1˙955˙233 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIABELOOP FR (GRENOBLE) coordinator 1˙955˙233.00

Map

 Project objective

20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.

Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.

Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation. During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "D2P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "D2P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More